AGTC, a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced the appointment of Larry Bullock to the position of Chief Financial Officer.
Mr. Bullock has more than 30 years of financial executive management experience, including over two decades as a chief financial officer in the biotechnology industry.
Help employers find you! Check out all the jobs and post your resume.
